Neuromics offers a wide variety of cancer associated fibroblasts (CAFs) perfect for use in cancer research along with other areas of interest. In this post, we'd like to highlight our Lung CAFs, which were utilized in two articles published in the past week. Neuromics' selection of Lung CAFs includes Lung Adenocarcinoma CAFs (Cat.#CAF07A) and Lung Squamous Cell CAFs (Cat.#CAF07SC).  

Image: HDAC11 inhibitors prevent growth of cancer cells even in presence of CAFs. Treatment of 2D coculture of A549 (red) cells with primary lung CAFs (Green) (CAF07A) with 10 μM of FT234 show that the HDAC11 inhibitor selectively reduces the growth of A549 cells as compared to the Control co-cultures in 48 h. Such an effect was not observed in the negative control FT650 treatment. Image courtesy of Namrata Bora-Singhal, et al. Novel HDAC11 Inhibitors Suppress Lung Adenocarcinoma Stem Cell Self-Renewal and Overcome Drug Resistance by Suppressing Sox2. Scientific Reports, 10:4722. doi: 10.1038/s41598-020-61295-6

Learn more about these recent publications...

In the first publication, they use our Lung CAFs to explore a treatment option for tumors resistent to immunotherapy. By generating OMTX705, which is an antibody-drug conjugate, researchers found that by combining treatment of chemotherapy with OMTX705 led to an inhibition of tumor growth and tumor regression. In this study, they look at tumors with CAFs expressing fibroblast activating protein α (FAPα), which are known to be resistent to immunotherapy.

Image: Lung Adenocarcinoma (CAF07A-stained with a-SMA+dapi)

This second publication uses our Lung Adenocarcinoma CAFs (Cat.#CAF07A) when looking for new ways to treat non-small cell lung cancer (NSCLC). They find that depletion or inhibition of histone deacetylase 11 (HDAC11) reduces the presence of cancer stem sells (CSCs). These results hold even when CAFs were present, suggesting that inhibition of HDAC11 should be further explored in treating NSCLC.